Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.61 |
| ▸ | DRD2 | P14416 | 6/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25374458 | 0.94 | SIGMAR1 (0.67) | SIGMAR1DRD2CA1CA2CA7 | |
| SCHEMBL828979 | 0.93 | SIGMAR1 (0.66) | SIGMAR1DRD2CA1CA2CA7 | |
| SCHEMBL23673811 | 0.92 | SIGMAR1 (0.64) | SIGMAR1DRD2CA1CA2CA7 | |
| SCHEMBL29889007 | 0.91 | SIGMAR1 (0.56) | SIGMAR1DRD2CA1CA2CA7 | |
| SCHEMBL30091901 | 0.91 | SIGMAR1 (0.59) | SIGMAR1DRD2CA1CA2CA7 | |
| SCHEMBL22151422 | 0.90 | SIGMAR1 (0.62) | SIGMAR1DRD2CA1CA2CA7 | |
| SCHEMBL23728664 | 0.90 | SIGMAR1 (0.58) | SIGMAR1DRD2CA1CA2CA7 | |
| SCHEMBL29132198 | 0.86 | MEN1 (0.58) | SIGMAR1CA1CA2CA7ACKR3 | |
| SCHEMBL29132278 | 0.85 | SIGMAR1 (0.57) | SIGMAR1DRD2ACKR3HTT | |
| SCHEMBL30785030 | 0.85 | SIGMAR1 (0.70) | SIGMAR1HTTSYKMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230079107-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| WO-2020252393-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20130102605-A1 | INHIBITORS OF AKT ACTIVITY | LIANG PENG (CN) | 2013-04-25 | — | — | US | disclosed |
| US-20120028918-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) | 2012-02-02 | — | — | US | disclosed |
| US-20080275026-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. | 2008-11-06 | — | — | US | disclosed |
| US-7407949-B2 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2008-08-05 | — | — | US | disclosed |
| US-20060166971-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2006-07-27 | — | — | US | disclosed |
| EP-1592693-A1 | BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS | Ferring B.V. (NL) | 2005-11-09 | — | — | EP | disclosed |
| US-20050032777-A1 | Diazacycloalkanes as oxytocin agonists | FEERING B.V. (NL) | 2005-02-10 | — | — | US | disclosed |
| WO-2004072083-A1 | BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS | FERRING B.V. (NL) | 2004-08-26 | — | — | WO | disclosed |
| EP-1449844-A1 | benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2004-08-25 | — | — | EP | disclosed |
| EP-1421087-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003016316-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032777-A1 | Diazacycloalkanes as oxytocin agonists | OXTR, GNRHR, KISS1R | SIGMAR1 682/4885DRD2 444/4885CA1 3914/4885 |
| US-20080275026-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | AVPR1A, AVPR2, AVPR1B | SIGMAR1 251/4885DRD2 527/4885CA1 2814/4885 |
| US-20120028918-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | PIK3CA, G6PC1, PIK3C2B | SIGMAR1 3306/4885DRD2 3356/4885CA1 3613/4885 |
| US-20060166971-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | AVPR1A, AVPR2, AVPR1B | SIGMAR1 251/4885DRD2 527/4885CA1 2814/4885 |
| US-20130102605-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CA, PIK3CD, AKT2 | SIGMAR1 4675/4885DRD2 4711/4885CA1 2861/4885 |
| US-20230079107-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | FCGR3B, FCGR1A, FCGR2A | SIGMAR1 3786/4885DRD2 3947/4885CA1 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.